Feedback / Questions
T3011 - ImmVira Pharma
https://www.prnewswire.com/news-releases/immvira-announces-first-patient-dosed-in-a-multi-regional-phase-ii-clinical-trial-evaluating-mvr-t3011-oncolytic-immunotherapy-in-patients-with-bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer-nmibc-302477586.html
Jun 10, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next